• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Device thrombosis more likely with bioresorbable scaffolds versus drug-eluting stents

byDayton McMillan
June 16, 2017
in Cardiology, Chronic Disease, Imaging and Intervention, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Device thrombosis occurred at a higher rate in patients undergoing percutaneous coronary intervention (PCI) utilizing a bioabsorbable scaffold compared to a metallic stent, both of which were covered in everolimus.

2. Failure of vessel revascularization and cardiac death occurs at similar rates for PCI procedures utilizing bioresorbable scaffolds and metallic stents.

Evidence Rating: 1 (Excellent)

Study Rundown: Drug-eluting stents (DES) are commonly used in PCI for treating coronary artery disease (CAD), though their rigid intravascular structure is associated with a risk of reocclusion. A new type of device, bioresorbable scaffolds, could potentially improve vessel function without leaving a permanent intravascular structure prone to reocclusion. Prior work has been mixed regarding reocclusion rates of bioresorbable stents compared to DES. As bioresorbable scaffolds have become more widely approved, better comparison of devices utilized in routine clinical practice and with longer follow-up is needed.

This randomized study looked to compare rates of vessel reocclusion and complications of reocclusion for patients undergoing PCI using bioresorbable scaffolds and DES, both covered in the immunosuppressant everolimus. Patients included in the study had CAD deemed suitable for PCI. Comparing treatment groups at 2 years follow-up, no difference was observed between treatment groups regarding rates of target-vessel failure, revascularization, or cardiac death. Thrombosis was more likely in the bioresorbable scaffold group, as was target-vessel myocardial infarction (MI). This study suggests the pathologic process of thrombosis, and clinically significant target-vessel MI, may be more common in vessels treated with bioresorbable scaffolds. These results suggest further evaluation of bioresorbable scaffold efficacy is needed, even though rates of cardiac death and target-vessel failure occur at similar rates compared to DES.

Click to read the study, published in NEJM

Relevant Reading: Improving vessel healing with fully bioresorbable drug-eluting stents: more than a pipe dream?

RELATED REPORTS

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

2 Minute Medicine Rewind February 13, 2023

Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality

In-Depth [randomized controlled trial]: This noninferiority, randomized clinical trial enrolled 1845 patients in the Netherlands between 2013 and 2015. Enrolled patients had CAD and vascular lesions amenable to PCI. Randomization distributed patients in a 1:1 manner into bioresorbable vascular scaffold (n = 924) and drug-eluting stent (n = 921) treatment groups, and both devices were coated with everolimus. During the first year following placement, 63% of patients in the scaffold group had redilation procedures performed. Both groups received antiplatelet therapy per guidelines. Patients were followed for up to 5 years after the procedure to assess primary endpoints of cardiac death, target-vessel MI, and target-vessel failure, and secondary endpoints of device thrombosis and total death, MI, or revascularization events. Mean follow-up was 707 days. Target-vessel failure occurred in 105 scaffold patients and 94 stent patients (HR with bioresorbable scaffolds 1.12; 95%CI 0.85-1.48; p = 0.43). Cardiac death at 2 years occurred in 18 (2.0%) scaffold and 23 (2.7%) stent patients, respectively (HR 0.78; 95%CI 0.42-1.44; p = 0.43). Target-vessel MI occurred in 5.5% of scaffold and 3.2% of stent patients, respectively (HR, 1.60; 95%CI 1.01-2.53; p = 0.04). Definite or probable device thrombosis occurred at 2 years in 3.5% of scaffold and 0.9% of stent patients, respectively (HR, 3.87; 95%CI 1.78-8.42; p < 0.001).

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: drug eluting stentspercutaneous coronary interventionthrombosis
Previous Post

Self-monitoring of glucose in non-insulin dependent diabetics not linked to improved control

Next Post

Lipid nanoparticles deliver messenger RNA for hemophilia B protein replacement therapy [PreClinical]

RelatedReports

Endocrinology

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

March 24, 2023
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Weekly Rewinds

2 Minute Medicine Rewind February 13, 2023

February 13, 2023
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease
Cardiology

Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality

February 4, 2023
Cardiology

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

December 26, 2022
Next Post
Blood type correlates with egg reserve in infertile women

Lipid nanoparticles deliver messenger RNA for hemophilia B protein replacement therapy [PreClinical]

Radiofrequency ablation of hepatic metastases in colorectal cancer linked with improved survival

Low-cost biochip isolates cells for clinical diagnosis [PreClinical]

Ambrisentan found ineffective against idiopathic pulmonary fibrosis

Drug improves cystic fibrosis pulmonary inflammation and protein function [PreClinical]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options